<?xml version="1.0" encoding="UTF-8"?>
<rss xmlns:media="http://search.yahoo.com/mrss/" version="2.0">
<channel>
<title><![CDATA[RSS for Ranbaxy Laboratories]]></title>
<description><![CDATA[Watch breaking news videos and read news updates about Ranbaxy Laboratories on FOXBusiness.com.]]></description>
<link><![CDATA[http://www.foxbusiness.com/search-results/]]></link>
<atom:link xmlns:atom="http://www.w3.org/2005/Atom" type="application/rss+xml" rel="self" href="http://www.foxbusiness.com/search-results/urss?pageid=767800"/>
<item>
<title><![CDATA[U.S. Slaps Ban on Another Indian Drugmaker]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/23/us-slaps-ban-on-another-indian-drugmaker/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/23/us-slaps-ban-on-another-indian-drugmaker/</guid>
<pubDate><![CDATA[Thu, 23 May 2013 10:15:10 EDT]]></pubDate>
<description><![CDATA[The U.S. Food and Drug Administration slapped an import ban on Indian drugmaker Wockhardt Ltd. (532300.BY) after one of the company's plants failed an FDA safety inspection.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Ranbaxy to Pay $500 Million in Adulterated Drugs Case]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/13/ranbaxy-to-pay-500-million-in-adulterated-drugs-case/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/13/ranbaxy-to-pay-500-million-in-adulterated-drugs-case/</guid>
<pubDate><![CDATA[Mon, 13 May 2013 13:05:03 EDT]]></pubDate>
<description><![CDATA[Indian generic pharmaceutical maker Ranbaxy Laboratories Ltd.'s (500359.BY) U.S. subsidiary has pled guilty to felony charges relating to adulterated drugs made at two of Ranbaxy's manufacturing facilities in India, according to the Department of Justice.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Ranbaxy to Pay $500 Million in Adulterated Drugs Case; Largest Such Settlement Ever]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/13/ranbaxy-to-pay-500-million-in-adulterated-drugs-case-largest-such-settlement/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/13/ranbaxy-to-pay-500-million-in-adulterated-drugs-case-largest-such-settlement/</guid>
<pubDate><![CDATA[Mon, 13 May 2013 12:51:02 EDT]]></pubDate>
<description><![CDATA[Indian generic pharmaceutical maker Ranbaxy Laboratories Ltd.'s (500359.BY) U.S. subsidiary has pled guilty to felony charges relating to adulterated drugs made at two of Ranbaxy's manufacturing facilities in India, according to the Department of Justice.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Astellas, Daiichi Sankyo See New Drugs Propelling Growth]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/05/13/astellas-daiichi-sankyo-see-new-drugs-propelling-growth/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/05/13/astellas-daiichi-sankyo-see-new-drugs-propelling-growth/</guid>
<pubDate><![CDATA[Mon, 13 May 2013 08:15:08 EDT]]></pubDate>
<description><![CDATA[Japan's second and third largest drug makers on Monday predicted growth in the current fiscal year as they battle to offset large-scale revenue fallout from patent expiries with solid sales of new drugs.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Novartis Boosted by Drug Launches]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/04/24/novartis-boosted-by-drug-launches/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/04/24/novartis-boosted-by-drug-launches/</guid>
<pubDate><![CDATA[Wed, 24 Apr 2013 06:35:06 EDT]]></pubDate>
<description><![CDATA[Swiss drug maker Novartis AG (NOVN.VX) Wednesday posted a rise in first-quarter net profit, as new product launches and strength in emerging markets helped offset declining sales of the blockbuster heart drug Diovan.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Ranbaxy Resumes Generic Lipitor Production for U.S.]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2013/02/22/ranbaxy-resumes-generic-lipitor-production-for-us/?]]></link>
<guid>http://www.foxbusiness.com/news/2013/02/22/ranbaxy-resumes-generic-lipitor-production-for-us/</guid>
<pubDate><![CDATA[Fri, 22 Feb 2013 12:05:04 EST]]></pubDate>
<description><![CDATA[Ranbaxy Laboratories Ltd. (500359.BY) said Friday it has resumed manufacturing generic copies of the cholesterol-lowering drug Lipitor for the U.S. market, following a production suspension late last year after tiny glass particles were found in the product.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Ranbaxy Had Smaller Recall of Generic Lipitor in August Over Pill Mix-up]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/11/29/ranbaxy-had-smaller-recall-generic-lipitor-in-august-over-pill-mix-up/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/11/29/ranbaxy-had-smaller-recall-generic-lipitor-in-august-over-pill-mix-up/</guid>
<pubDate><![CDATA[Thu, 29 Nov 2012 12:26:06 EST]]></pubDate>
<description><![CDATA[Ranbaxy Laboratories Ltd. (500359.BY) recalled more than 32,000 bottles of its generic version of cholesterol-lowering drug Lipitor over a potential pill mix-up in August--nearly three months before a larger recall for the presence of small glass particles in some bottles.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Malaysia Unveils MYR5.61 Billion of Investments Via 7 New Projects]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/09/13/malaysia-unveils-myr561-billion-investments-via-7-new-projects/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/09/13/malaysia-unveils-myr561-billion-investments-via-7-new-projects/</guid>
<pubDate><![CDATA[Thu, 13 Sep 2012 07:39:00 EDT]]></pubDate>
<description><![CDATA[Malaysia Thursday announced seven new projects worth a total of 5.61 billion ringgit ($1.82 billion) ranging from a liquefied natural gas terminal to a drug manufacturing plant, as part of its broader ambition to become a high-income economy by 2020.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Malaysia PM: Attracted 7 New Projects Worth MYR5.61 Billion]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/09/13/malaysia-pm-attracted-7-new-projects-worth-myr561-billion/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/09/13/malaysia-pm-attracted-7-new-projects-worth-myr561-billion/</guid>
<pubDate><![CDATA[Thu, 13 Sep 2012 04:44:26 EDT]]></pubDate>
<description><![CDATA[Malaysia announced Thursday a slew of new projects worth a total of 5.61 billion Malaysian ringgit ($1.82 billion) in investments, as part of its broader ambition to become a high-income economy by 2020.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Pfizer Sued for Conspiring to Delay Generic Lipitor]]></title>
<link><![CDATA[http://www.foxbusiness.com/industries/2012/07/06/pfizer-sued-for-conspiring-to-delay-generic-lipitor/?]]></link>
<guid>http://www.foxbusiness.com/industries/2012/07/06/pfizer-sued-for-conspiring-to-delay-generic-lipitor/</guid>
<pubDate><![CDATA[Fri, 06 Jul 2012 09:28:57 EDT]]></pubDate>
<description><![CDATA[Pfizer has been sued by five big retailers for allegedly conspiring to delay sales of generic versions of popular heart drug Lipitor.]]></description>
<media:thumbnail>http://global.fncstatic.com/static/managed/img/fb2/Pfizer-Pharmaceuticals-World-Headquarters-01.jpg</media:thumbnail>
</item>
<item>
<title><![CDATA[Dr Reddy's Jan-March Net Grows 2.7%; Misses View On One-Time Charge]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/05/11/dr-reddy-jan-march-net-grows-27-misses-view-on-one-time-charge/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/05/11/dr-reddy-jan-march-net-grows-27-misses-view-on-one-time-charge/</guid>
<pubDate><![CDATA[Fri, 11 May 2012 08:40:05 EDT]]></pubDate>
<description><![CDATA[Dr. Reddy's Laboratories Ltd. (500124.BY) Friday disappointed investors with a slim 2.7% rise in its fourth-quarter net profit, but this was due mainly to a one-time charge.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Teva 1Q Profit Up 13% On Branded, Generic Drug Sales]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/05/09/teva-1q-profit-up-13-on-branded-generic-drug-sales/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/05/09/teva-1q-profit-up-13-on-branded-generic-drug-sales/</guid>
<pubDate><![CDATA[Wed, 09 May 2012 09:53:20 EDT]]></pubDate>
<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) said Wednesday its first-quarter profit rose 13%, as sales growth for branded and generic drugs in the U.S. and emerging markets helped offset Europe's poor performance.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/05/01/pfizer-profit-falls-1-as-generics-hurt-lipitor-sales/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/05/01/pfizer-profit-falls-1-as-generics-hurt-lipitor-sales/</guid>
<pubDate><![CDATA[Tue, 01 May 2012 11:50:41 EDT]]></pubDate>
<description><![CDATA[Pfizer Inc.'s (PFE) first-quarter profit declined 19% as sales of its top product, the cholesterol-lowering drug Lipitor, tumbled 71% in the U.S. due to competition from generic copies.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[UPDATE: Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/05/01/update-pfizer-profit-falls-1-as-generics-hurt-lipitor-sales/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/05/01/update-pfizer-profit-falls-1-as-generics-hurt-lipitor-sales/</guid>
<pubDate><![CDATA[Tue, 01 May 2012 11:47:21 EDT]]></pubDate>
<description><![CDATA[("UPDATE: Pfizer Profit Falls 19% As Generics Hurt Lipitor Sales," published at 9:01 a.m.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Ranbaxy Starts Selling Generic Atorvastatin In Australia]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/02/21/ranbaxy-starts-selling-generic-atorvastatin-in-australia/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/02/21/ranbaxy-starts-selling-generic-atorvastatin-in-australia/</guid>
<pubDate><![CDATA[Tue, 21 Feb 2012 01:25:37 EST]]></pubDate>
<description><![CDATA[India's Ranbaxy Laboratories Ltd. (500359.BY) Tuesday said it has become the first generic drug maker to started selling generic cholesterol drug atorvastatin in Australia.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Watson Pharma 4Q Profit Surges On Generic Lipitor, Concerta]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/02/14/watson-pharma-4q-profit-surges-on-generic-lipitor-concerta/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/02/14/watson-pharma-4q-profit-surges-on-generic-lipitor-concerta/</guid>
<pubDate><![CDATA[Tue, 14 Feb 2012 10:24:39 EST]]></pubDate>
<description><![CDATA[Watson Pharmaceuticals Inc.'s (WPI) fourth-quarter profit surged as the introduction of a generic version of Pfizer Inc.'s (PFE) cholesterol drug Lipitor and other products boosted sales by more than 60%.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Japan Stocks Open Lower, With Earnings Dragging]]></title>
<link><![CDATA[http://www.foxbusiness.com/markets/2012/01/31/japan-stocks-open-lower-with-earnings-dragging/?]]></link>
<guid>http://www.foxbusiness.com/markets/2012/01/31/japan-stocks-open-lower-with-earnings-dragging/</guid>
<pubDate><![CDATA[Tue, 31 Jan 2012 19:18:00 EST]]></pubDate>
<description><![CDATA[Japanese stocks moved lower in early Wednesday trading, with a weak finish on Wall Street and disappointing earnings at home weighing on the market.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Patent Losses Hit Pfizer, Lilly As Both Await Alzheimer's Drug Data]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/01/31/patent-losses-hit-pfizer-lilly-as-both-await-alzheimers-drug-data/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/01/31/patent-losses-hit-pfizer-lilly-as-both-await-alzheimers-drug-data/</guid>
<pubDate><![CDATA[Tue, 31 Jan 2012 14:07:02 EST]]></pubDate>
<description><![CDATA[Drug makers Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY) fell off the so-called "patent cliff," each reporting declines in fourth-quarter profits due to new generic competition for top-selling drugs.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Pfizer 4Q Profit Slumps 50% As Lipitor Sales Decline]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/01/31/pfizer-4q-profit-slumps-50-as-lipitor-sales-decline/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/01/31/pfizer-4q-profit-slumps-50-as-lipitor-sales-decline/</guid>
<pubDate><![CDATA[Tue, 31 Jan 2012 09:34:15 EST]]></pubDate>
<description><![CDATA[Pfizer Inc.'s (PFE) fourth-quarter profit declined 50% as sales of its widely used cholesterol drug Lipitor tumbled due to new generic competition.]]></description>
<media:thumbnail/>
</item>
<item>
<title><![CDATA[Benefit Manager's Lipitor Move Highlights Pressure On Pfizer]]></title>
<link><![CDATA[http://www.foxbusiness.com/news/2012/01/27/benefit-managers-lipitor-move-highlights-pressure-on-pfizer/?]]></link>
<guid>http://www.foxbusiness.com/news/2012/01/27/benefit-managers-lipitor-move-highlights-pressure-on-pfizer/</guid>
<pubDate><![CDATA[Fri, 27 Jan 2012 18:01:15 EST]]></pubDate>
<description><![CDATA[Pharmacy-benefit manager Express Scripts Inc. (ESRX) will soon make an adjustment that raises out-of-pocket costs for some customers filling prescriptions of Pfizer Inc.'s (PFE) cholesterol-lowering drug Lipitor, underscoring the drug maker's challenge of keeping sales high in the face of generic competition.]]></description>
<media:thumbnail/>
</item>
</channel>
</rss>
